According to the latest research by InsightAce Analytic, the global Clinical Trial Imaging Services market is valued at US$ 1.37 billion in 2021, and it is expected to grow with a CAGR of 6.39% during a forecast period of 2022-2030. Clinical Trial is a protocol that studies new treatments and tests and checks their effects on human health. Clinical trials are used to treat cardiovascular diseases, cancer therapies, and many other health conditions. It is also an important part of the drug development process. The imaging technique is a key factor in clinical trials. The clinical trial imaging technique offers data accuracy, adaptability, consistency, and compliance to clinical studies. The global clinical trial imaging services market has been rising due to the advanced medical technologies, development, and new software launch.The factors such as increasing use of clinical trial imaging devices, adoption of advanced medical technologies, rising government investments for research and development of imaging services are expected to boost the market's growth over the forecast period. Furthermore, increased healthcare expenditure and the rising prevalence of human health diseases are fueling the growth of the clinical trial imaging services market. The high cost of clinical imaging service with advanced technologies and poor reimbursement policies can downscale the market growth during the Forecast period 2022-2030.
The Global clinical trial imaging services market is segmented into Service Types, Therapeutic areas, End-users, and regions. The Service Types segment is further bifurcated into Clinical Trial Design & Consultation Services, Reading &, Operational Imaging Services, Project & Data Management Services, and Other Service Types. Operational Imaging Services and Project & Data Management Services and are the main drivers of this market. In terms of Therapeutic areas, the market can be divided into Oncology, Neurology, Endocrinology, Analytical Services Cardiology, Gastroenterology, and Other Therapeutic Area. Oncology is the fastest-growing clinical trial imaging market segment due to the increasing prevalence of cancer, leading to growth in novel clinical trial imaging techniques.
Furthermore, the neurology segment is anticipated to boost the market, owing to the rise in the use of imaging in neurology clinical trials. By End-users, the market is segmented into Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, and Academic & Government Research Institutes. Pharmaceutical & Biotechnology Companies hold the largest share of this market. Based on the region, the clinical trial imaging services market is divided into North Pharmaceutical & Biotechnology Companies America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America dominated the global clinical trial imaging services market and will continue this trend over the forecast period, owing to ising adoption of advanced medical technologies, the increasing number of pharmaceutical companies, rand high clinical R&D investments by the government.
Some of the key Players of global clinical trial imaging services market are Biospective Inc., Calyx, Bioclinica Inc., Ert Clinical, Proscan Imaging, Ixico Plc, Intrinsic Imaging, Llc, Imaging Endpoints, Micron, Inc., Icon Plc., Medpace, Inc., Median Technologies, Pharmtrace, and other Prominent Player.
